Serial #79346632
LIVE

Serial Number

79346632

Owner

Albumedix Ltd

Attorney

Karen Lim

Filing Date

May 20, 2022

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79346632 Trademark

Serial Number: 79346632 • Registration: 7532408

Serial #79346632 is a trademark filed by Albumedix Ltd on May 20, 2022. The trademark is classified under Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Albumedix Ltd (16 trademarks)

HQ, Mabel Street

Entity Type: 99

Trademark Details

Filing Date

May 20, 2022

Registration Date

October 15, 2024

Published for Opposition

July 30, 2024

Goods & Services

Research and development services in the field of new biological, pharmaceutical, biopharmaceutical, chemical and medical products; technological consultancy, namely, providing consultancy and expert assistance in the field of new product development of medicines and pharmaceutical products, and laboratory analysis in the field of medicines and pharmaceuticals; research, development and laboratory analysis services relating to pharmaceutical and medicinal goods, in particular, albumin, chemicals, peptides, proteins, antibodies, cells, nucleic acids, viruses, live viruses, live-attenuated viruses, attenuated viruses, virus-like particles and viral vectors; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control in the field of pharmaceutical, biopharmaceutical, chemical, and medical products; certification, namely, quality control services in the field of biological, pharmaceutical, biopharmaceutical, chemical, and medical products; certification, namely, quality assurance services in the field of biological, pharmaceutical, biopharmaceutical, chemical, and medical products; process monitoring, namely, quality assurance in the field of biological, pharmaceutical, biopharmaceutical, chemical, and medical products; quality control services for others in the field of development and testing of cells; services of a scientific, chemical and biological laboratory; development and testing of chemical, pharmaceutical, biopharmaceutical, chemical and medical production methods; quality control services for others and authentication services in the field of biological, pharmaceutical, biopharmaceutical, chemical, and medical products; process monitoring, namely, providing quality assurance services in the field of biological, pharmaceutical, biopharmaceutical, chemical, and medical products; scientific and medical laboratory services; information, consultancy and advisory services for the aforementioned services

Regulatory compliance auditing; regulatory compliance consultancy in the field of biotechnology, pharmaceuticals, biopharmaceuticals, and medical testing and research; reviewing standards and practices to assure compliance with laws and regulations in the fields of biology, pharmaceuticals, biopharmaceuticals, chemicals, and medicine; information, consultancy and advisory services for the aforementioned services

Education, namely, classes, seminars, and workshops in the fields of biology, medicine, biologicals, biopharmaceuticals, pharmaceuticals, and chemical analysis; providing of training in the fields of biology, medicine, biologicals, biopharmaceuticals, pharmaceuticals, and chemical analysis; teaching and training in the fields of biology, medicine, biologicals, biopharmaceuticals, pharmaceuticals and chemical analysis; teaching and training in the fields of development and use of vaccines, growth factors, immune modulators, monoclonal antibodies, cells, cell therapies, tissues, proteins, recombinant proteins, nucleic acids, gene therapies, products derived from living culture systems, products derived from human blood, products derived from plasma; provision of medical, biological, biopharmaceutical, pharmaceutical and chemical instruction courses; organization of educational conferences in the fields of medical, biological, biopharmaceutical, pharmaceutical and chemical research and development; technical training in the field of medical, biological, biopharmaceutical, pharmaceutical and chemical analysis; information, consultancy and advisory services for the aforementioned services

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 16, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 16, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 16, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 16, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 16, 2025 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 12, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 20, 2025 FICS
FINAL DISPOSITION PROCESSED
Mar 20, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 15, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 15, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 15, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 30, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jul 30, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 10, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 25, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 24, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jun 24, 2024 ERFR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 29, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 10, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 10, 2024 OPNR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 31, 2023 GNFN
FINAL REFUSAL E-MAILED
Dec 31, 2023 GNFR
FINAL REFUSAL WRITTEN
Dec 31, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 3, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 3, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 3, 2023 TROA
REFUSAL PROCESSED BY IB
May 24, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 4, 2023 RFCS
REFUSAL PROCESSED BY MPU
May 4, 2023 RFRR
NEW REPRESENTATIVE AT IB RECEIVED
Apr 2, 2023 NREP
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 16, 2023 RFCR
NON-FINAL ACTION WRITTEN
Mar 15, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 7, 2023 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Jan 29, 2023 NREP
APPLICATION FILING RECEIPT MAILED
Aug 9, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 5, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 4, 2022 REPR